A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration ...

NHS England has published updated medical retinal treatment pathway recommendations for wet age-related macular degeneration (wAMD), with pathways for diabetic macular oedema (DMO) and retinal vein ...

"Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy" was originally created and published by ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

A new study reveals that increasing levels of apolipoprotein M (ApoM) may slow or prevent the progression of age-related macular degeneration (AMD), a major cause of blindness in older adults.

Findings could help explain the links between macular degeneration and cardiovascular disease, which both worsen with age.

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints.

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints.